瑞舒伐他汀钙治疗冠状动脉弥漫性病变疗效分析  

Effect of rosuvastatin calcium in treatment of diffused coronary artery disease

作　　者：王红艳[1] 

机构地区：[1]河南省济源市人民医院心内科,河南济源459000

出　　处：《中国现代医生》2015年第6期100-102,共3页China Modern Doctor

摘　　要：目的分析瑞舒伐他汀钙治疗冠状动脉弥漫性病变患者超敏C反应蛋白（hs-CRP）的变化。方法选择2014年2-5月我院收治的160例行冠状动脉造影患者,术前均检测hs-CRP。其中80例为观察组,造影结果为三支血管狭窄程度均〉50%,病变长度均≥20 mm。予以瑞舒伐他汀钙10 mg/d治疗6个月。80例为对照组,冠状动脉造影结果完全正常。观察两组hs-CRP表达水平及观察组治疗后hs-CRP表达的变化。结果观察组与对照组治疗前血清hs-CRP分别为（7.39±2.46）mg/L、（4.39±0.89）mg/L,差异有统计学意义（P〈0.01）。观察组治疗后6个月血清hs-CRP降至（4.26±0.33）mg/L,治疗后hs-CRP表达水平较治疗前差异有统计学意义（P〈0.05）。观察组治疗后6个月TC、TG、LDL-C与治疗前比较差异有统计学意义（P〈0.05）。结论 hs-CRP在DCAD的发生和发展中起重要作用,瑞舒伐他汀钙能够显著降低hs-CRP表达水平,从而降低主要不良心血管事件,改善患者的预后。Objective To observe the clinical curative effect of rosuvastatin therapy on diffused coronary artery disease and the change of high sensitivity C-reactive protein. Methods A total of 160 cases of hospital patients in our hospital from February to May 2014 diagnosed diffused coronary artery disease by coronary artery angiography were ran domly divided into the treatment group and the control group, the levels of high segtive C-reactive protein were detect ed in serum using commercially available detection kits before operation. 80 cases in treatment group, angiographic results of three vascular stenosis was 50%, lesion length was ≥20 mm, and they were treated with rosuvastatin 10 mg/d for six months. Other 80 cases as control group, coronary angiography were normal completely. The hs-CRP changes of two groups and postoperation of treatment group were observed. Results The hs-CRP level of treatment group and control group before operation were（7.39±2.46）mg/L,（4.39±0.89） mg/L, there were significant differences（P0.01）. The hs-CRP level of treatment group declined to（4.26 ±0.33）mg/L after operation six months later, with significantly higher than that before operation, there were significant difference（P〈0.05）. The TC, TG, LDL-C levels of treatmeat group after operation six months had significant differences with before treament（P〈0.05）. Conclusion The hs-CRP plays a important role in occurring and developing of DCAD, which can be decreased by using rosuvastatin to reduce major adverse cardiovascular events, improve patients＇ outcomes.

关 键 词：瑞舒伐他汀钙 冠心病 HS-CRP 

分 类 号：R541.4[医药卫生—心血管疾病]